Results: Six hundred and eighty-two patients were randomized and analysed for the primary end point. There were no differences in comprehension rates (MFP static 
| BACKGROUND
Patient involvement is particularly indicated in medical decisions comprising more than one option usually including the option of watchful waiting.
1 Medical reasoning might be capable of comparing treatment efficacy with regard to a defined outcome parameter. The patient's opinion is needed to weigh up the values of different outcomes with potential side-effects. This applies even more for complexly structured decisions and/or for decisions associated with pronounced scientific uncertainty such as in the case of multiple sclerosis treatments.
Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease starting predominantly in young adults. Apart from symptomatic therapies, the range of treatments comprises an increasing variety of immunotherapeutic options. Making decisions amongst them is challenging with regard to putative risks and uncertain benefit. 2, 3 Comparison of drugs is a complex endeavour as few comparative studies exist and even less evaluating treatment escalation series or longterm effects of immunotherapies.
To be able to make informed choices about immunotherapies, MS patients need information prepared in line with the criteria of evidence-based patient information. 4, 5 These criteria require communication of benefits and harm for each option presented as changes of absolute risk together with an estimation of the information's trustworthiness. Furthermore, the criteria include presenting event rates
by the additional use of graphical frequency formats. Previous studies have shown that different graphical formats visualizing probabilistic information using bar graphs, survival curves and pie charts 4, 6 improve patients' understanding 7 and even the quality of physician patient communication 8, 9 when compared to text-only risk informa- MFPs are better suited to conveying the message of uncertainty about whether or not an individual will belong to the benefit group. 12 There are, however, practical drawbacks associated with using MFPs, particularly in multiple-option decisions like those addressed in our previous studies. [13] [14] [15] As the number of three consecutive MFPs needed to present the benefit of a single option ( Figure 1 ) multiplies with the number of outcomes reported for benefit and harm and the number of available options, information materials easily become long and difficult to comprehend. 16 Also, elements of MFPs, that is stick figures or smileys, do not indicate the nature of clinical outcomes (eg in the MS example "disease progression" or "relapses") and therefore need additional explanations in the graphic's legend. Based on the elaborate qualitative design methodology, 17 we recently introduced CLARIFIG (clarifying risk figures) combining advantages of both proportional bar graphs and stick figure icons in a new space-saving format.
This article reports on an investigation aiming to evaluate the new presentation format's efficacy with regard to communicating study effects comprehensibly. Comprehension was defined in terms of accuracy of understanding the given quantities and time needed to process and complete the task. The first research question was: Does CLARIFIG lead to better comprehension and faster processing compared to MFP as the gold standard? Considering the increasing importance of making patient information tools feasible for web-based presentation, we also aimed at elucidating possible advantages of a stepwise animation.
Our second research question was: Does animated presentation lead to better comprehension and faster processing than static presentation? benefit of two years' interferon treatment in terms of progression:
| METHODS

| Design
The study used a web-based four arm randomized controlled trial ( Figure 2 ) using a basic information example considering the effect of interferon-beta treatment in slowing disease progression in MS. 18 The previously tested basic example of CLARIFIG ( Figure 3 ) was compared with a corresponding application of the MFP reference standard ( Figure 1 ) and with animated versions of the two graphs, respectively.
The study was part of a research project within the German Multiple Sclerosis Competence network on decision coaching on immunotherapies in MS, which was approved by the Ethics Committee of the Hamburg Chamber of Physicians (PV4576). The information displayed in Figure 3 can be summarized by saying that nine of 100 patients benefit (blue bar segment/thumb up) and another 91 do not benefit (yellow segment) but present in two conditions, stable (hands behind the back) and progressed (icon with stick).
| Intervention
The study tested the identical application of the CLARIFIG graph previously used during its development.
| Sample
To allow for a representative sample of people with MS, we used only two self-reported inclusion criteria: age ≥18 and a confirmed diagnosis of MS. The sample size was calculated based on the results of the pre-test. Accordingly, N=143 participants were needed in each group to detect a difference between 10% and 25% of the participants meeting the primary end point. The calculation was based on two-sided testing with a 5% alpha error and a 90% power. Compensating a 20% dropout rate, this calculation resulted in a proposed sample size of N=686 participants. 
| Procedure
Web presentation of the study was programmed using Unipark soft- Although stable during interferon treatment, patients might not benefit, because … … it is uncertain, whether those patients' extent of disability will increase in the future.
… those patients are not cured though.
… their condition did not improve.
… they would have been stable during that time even without treatment. No benefit Benefit the questionnaire, the system registered a participant as a finisher.
However, before the procedure was officially finished, participants were additionally asked to fill in a numeracy questionnaire.
| Measurements
The primary end point was previously developed and tested as a measure of accurate comprehension of the given quantitative information. 17 The score was dichotomized, defining four correct answers to the given set of four questions as correct and any other combination as false including missing answers. Beyond the recall of the pure quantity of benefit, the measure requires full comprehension of the complementary frequencies of patients without benefit.
Mostly challenging (lowest estimate of item difficulty) was item 4, a multiple-choice question assessing understanding of the possibility of "no benefit" even though patients remained stable (Figure 4 ). Our previous qualitative research found the idea that the actual medical result cannot necessarily be equated with benefit to be counterintuitive at first glance and therefore difficult to understand. The secondary end point, processing time, was measured from the start of the study presentation and until completion of the primary end point questionnaire. Systematic variation of the time needed to complete the task was caused only by the presentation format, as all other parts of the study were identical. Differences in processing time were considered important, although the type of hardware used as well as connection speed might have led to individual differences, but no differences between groups were expected due to randomization. Disability was assessed with an eight-step ordinal measure based on the CAMBS scale. 20 To assess subjectively perceived cognitive impairment, four ordinally scaled items of the HAQUAMS instrument were applied. 21 In addition, the questionnaire assessed age, education, disease course, disease duration, medication status and previous participation in related studies. Numeracy was assessed using five of nine dichotomous test items from the Berlin Numeracy scale. 
| Analyses
Descriptive statistics were used to characterize the sample and the four study groups (Table 1) with regard to demography, diseaserelated data and numeracy. In the data matrix used by the statisticians analysing the trial, the nature of the four conditions was disguised. Participants were included in the analyses of the primary end point if they at least reached the place where the four-item comprehension test was provided. Missing values were counted as "not correct." Analyses of primary and secondary end points were conducted pairwise within the relevant factor steps. Fisher's exact tests were applied to test for the effects of the frequency format on comprehension separately for the two presentation types. T tests for unpaired samples were applied to test for effects of the frequency format on processing time. However, only finishers with correct results were included in this analysis. The impact of the presentation type (static vs animated) was tested separately for the two formats using Fisher's exact tests for comprehension and unpaired t tests for processing time.
The influence of numeracy and cognitive impairment was tested using unpaired t tests between subgroups of participants meeting and not meeting the primary end point and divided by median split of processing time, respectively.
Moderation of the rate of primary end point achievement by education or disease progression was tested using Fisher's exact tests, moderation of the secondary end point using ANOVA.
All statistical analyses were conducted using IBM Corp. Released 
| RESULTS
Of 889 interested visitors, 682 completed the demographic questionnaire, fulfilled the inclusion criteria and were randomized. About 658 completed the study (for demographic data see Table 1 ) by at least finishing the primary end point task. 
| Primary end point
The two formats did not differ with regard to frequencies of comprehension, neither in the static nor in the animated presentation (MFP static =46%, CLARIFIG static =44%; P=.59; animated MFP animated =23%, CLARIFIG animated =30%; P=.134) ( Table 2 ). Single correct answers within the four-item comprehension questionnaire were more frequent; 85% of the participants identified the correct number of patients benefiting from treatment ( Table 2 ).
For the static presentation, the animated formats led to significantly less comprehension and longer processing time (MFP: P≤.001). However, compared to the static presentation, the animated formats led to significantly less comprehension and longer processing time (MFP: p <= .001 / .001, CALRIFIG: p = .027/.017) ( correctly identified the proportion benefiting (9%), while <50% of participants in all conditions fully understood this figure was clearly below 50% in all conditions. We are not aware of other studies using the latter instead of the former parameter to assess understanding of numerical risk information. However, our choice of the more rigorous parameter as the primary end point reflects our claim to enable patients to make informed choices. As this requires knowledge about both the absolute rate of benefit and the natural course, our end point was meant to assess complete understanding of the graph. of fundamental numerical skills in a high percentage of the public. The study is strong with regard to large sample size and the low dropout rate, but might be challenged with regard to the representativeness of the study population. Because of the web-based approach, only patients with a special interest or competence might have accessed the study. Most of the patients in our sample probably were not currently involved in making decisions about immunotherapy, which might have limited the motivation to process the information and might have led to underestimation of the total comprehension rate.
| Secondary end point
| DISCUSSION
By only looking at two end points (comprehension and processing time), the present study failed to investigate the new graph's possible impact on a number of reasonable end points, such as perception of uncertainty, motivation to take an active role in the decision-making process, memorability of the information and transfer competence.
Most importantly, however, its impact on the decision-making process in terms of facilitating shared decision making, informed choices and realistic expectation should be focused in further studies.
Effects of frequency formats on risk perception are not yet fully understood, 12, 33 and the optimal format has not yet been found.
6
Moreover, as the context of the information, the target group and even the numerator size itself moderate the formats' suitability, current evidence is far from being able to inform systematic recommendations for developers and users of frequency formats. 6 In this respect, our study responds to a persistent lack of comparative studies and systematic developments in the field of communication and understanding of frequency formats.
In summary, the new format is promising because it has undergone a sound development process involving patients and a rigorous evaluation within a randomized controlled trial. As is immediately evident, CLARIFIG complies with the criteria of evidence-based patient information, 4 but also shows practical advantages with regard to multipleformat arrangements in limited space.
| CONCLUSION
Comprehension and processing speed of the new format, CLARIFIG, is comparable to commonly used multifigure pictographs (MFPs). The new format is advantageous with regard to space requirements and will facilitate the comparison of different treatment options in comprehensive patient information. This trial is considered exploratory as it compared the methods in a limited application using information from just one isolated study. Having found low comprehension rates irrespective of the experimental condition, the study demonstrates the gap between recognizing and fully understanding the information on the rate of benefit. This result implies that further research is needed on strategies to establish realistic expectations regarding the disease's natural course. Moreover, further studies are needed to prove the format's advantages in more complex contexts such as patient decision aids presenting information on various treatment options in parallel and in other medical domains.
